Odylia Therapeutics
Rare diseases
Patient population
No data available.
About us
Odylia is a nonprofit dedicated to accelerating treatments for rare diseases through two core initiatives: the Odylia Pipeline and Brydge Solutions. Our internal pipeline includes three gene therapy programs. Through Brydge Solutions, we offer drug development expertise to the broader rare disease community, enabling progress through flexible and collaborative partnerships. We measure success through shortened timelines, lower costs, and fewer terminated programs in the rare disease space.
Website
Therapeutics of interest
Therapeutics in development
Members
Ashley Winslow
Flawnson Tong
Research plans
Title | Research strategy | Stage | Status | Partners | Description | Links | Number of projects |
|---|---|---|---|---|---|---|---|
OT004-RPGRIP1 Gene Therapy | Gene replacement therapy | Pre-clinical | Seeking partners (sponsors, fundraising, licensing, etc.) | -- | Odylia is developing a gene therapy to treat vision loss caused by RPGRIP1 mutations, for which there is currently no treatment. This gene therapy uses the novel Anc80 vector technology. Odylia is currently conducting late-stage preclinical experiments and is preparing for IND submission for use of the gene therapy in clinical trials. | ||
OT101- USH1C Gene Therapy Program | Gene replacement therapy | Pre-clinical | Ongoing |
| To address the lack of treatments for this disease, Odylia is developing a gene therapy to prevent vision loss caused by mutations in the USH1C gene. In collaboration with researchers at Johannes Gutenberg-University Mainz, Technical University Munich, Academy of Sciences of the Czech Republic, and the University of Tübingen, Odylia is testing the therapeutic potential of a subretinal gene therapy in a genetic model of Usher Syndrome Type 1C. |